Kairos Pharma Announces Virtual KOL Event to Provide Perspectives on ENV105 Interim Efficacy Results in Advanced Prostate Cancer
KAPA(KAPA) LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that it will host a premier KOL event on Thursday, Sept. 18th at 5 p.m. ET / 2 p.m. PT to discuss diverse perspectives on the Company’s interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. Registration is required to participate in the webcast. Interest
Kairos Pharma Announces Presentation of New Phase 1 Data on ENV105 Combination Therapy in Non-Small Cell Lung Cancer at the World Lung Cancer Conference September 6-9, 2025
KAPA(KAPA) LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation of initial Phase 1 data of ENV105 in non-small cell lung cancer by Principal Investigator Dr. Karen Reckamp. Dr. Reckamp will present at the World Lung Cancer Conference which takes place September 6-9, 2025, at the Fira de Barcelona Gran Via in Barcelona, Spain. Dr. Reckamp’s presentation, “
Kairos Pharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference
KAPA(KAPA) LOS ANGELES--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces that John Yu, MD, CEO and Chairman, will present a corporate overview at the H.C. Wainwright 27th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel. Presentation Date: September 5, 2025 Time: Available on-demand starting at 7:00 AM Eastern Time
Kairos Pharma Presents Data On Investigational Small Molecule GITR Ligand Agonist KROS101 At 2025 ASCO Annual Meeting
KAPAKairos Pharma Q1 EPS $(0.08) Misses $(0.05) Estimate
KAPAKairos Pharma Issues Letter To Stockholders; Updates Two Ongoing Clinical Trials For ENV105 For Patients With Prostate Cancer And KROS101 For Cancer Treatment
KAPAKairos Pharma Ltd. Announces $876,000 Department Of Defense Grant To Support Its Study Of ENV105 To Prevent Drug Resistance In Lung Cancer
KAPAD. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
KAPAHC Wainwright & Co. Initiates Coverage On Kairos Pharma with Buy Rating, Announces Price Target of $12
KAPAD. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
KAPAKairos Advances Prostate Cancer Trial, Testing New Combo Treatment for Toughest Cases
KAPAMaxim Group Initiates Coverage On Kairos Pharma with Buy Rating, Announces Price Target of $4
KAPAD. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
KAPAD. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
KAPAKairos Pharma Presents Preclinical Data On Its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds' Potential As Therapeutics For Melanoma And Glioblastoma
KAPAD. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
KAPAD. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
KAPAKairos Pharma To Present At The Lytham Partners Investor Healthcare Summit On Monday, January 13, 2025 At 2:00 p.m ET
KAPAD. Boral Capital Maintains Buy on Kairos Pharma, Maintains $9 Price Target
KAPA